ECOR: Ascending Triangle detected on 5 Mar 2026

ECOR is forming an ascending triangle with a perfect overall score of 89 (structure: 15/15, breakout: 13/13, volume: 12/12). The stock trades at $7.98, near key resistance at $8.14, with critical support established at $5.43. Elevated volume at 77,603 shares (1.51x average) and rising MACD momentum (0.1607 histogram) confirm accumulation phase intensity. The 77% win probability and pristine pattern geometry position this as a high-confidence breakout setup in a bullish health care sector (regime score 0.59) with neutral broader market conditions.

electroCore reported preliminary full-year 2025 revenue of $31.8–$32.0 million, representing ~26% growth versus 2024. Net sales of $8.7 million in Q3 2025 increased 33% YoY. Analyst consensus is bullish: 5 of 5 Wall Street analysts rate ECOR as Buy (no Sells or Holds), with median price target of $20.00 and 12-month target of $22.0 (303% upside from current levels). Forecast revenue growth of 36.72% beats the medical device industry average of 8.48%. The company will announce Q4/FY2025 earnings on March 11, 2026, providing a near-term catalyst. Recent clinical validation includes a new study with Acacia Clinics and the Vagus Nerve Society testing gammaCore Sapphire for PTSD treatment, expanding therapeutic applications beyond migraine and headache indications. This fundamentally strong backdrop drives price structure formation.

A successful ascending triangle breakout above $8.14 resistance would target $8.38 (conservative measured move). Volume confirmation is critical—sustained daily volume >60,000 shares would validate the breakout thrust. The 77.41% historical win probability suggests mean reversion favors bulls. Invalidation occurs on a daily close below the $5.43 support level; loss of the upper triangle boundary with reduced volume would signal premature reversal. RSI at 68.11 shows strength without overbought extremes (>70), preserving upside runway. Pattern structure deterioration or breakdown below the ascending trendline would negate the setup before target achievement.

Analysts forecast ECOR EPS of -$1.44 for 2026 (range: -$1.62 to -$1.22); the company remains unprofitable. Zacks Research downgraded ECOR to 'strong sell' on January 28, 2026, creating divergence with bullish consensus. TAC-STIM revenue declined 32% YoY from $1.7M to $1.2M in 2024, signaling weakness in the wellness segment. Cash balances fell to $11.6 million by December 31, 2025 from $13.2 million in September, constraining operational runway if revenue deceleration accelerates. Beta of 1.15 and 20-day volatility of 85.24% amplify downside risk during sentiment reversals. Q3 2025 EPS of -$0.40 missed analyst expectations of -$0.38, warranting caution into the March 11 earnings call when 2026 guidance revision could trigger repricing.